These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 22641291)
1. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells. Christopherson RI; Mactier S; Almazi JG; Kohnke PL; Best OG; Mulligan SP Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):375-83. PubMed ID: 24940695 [TBL] [Abstract][Full Text] [Related]
3. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. Almazi JG; Alomari M; Belov L; Best OG; Shen Y; Graham ME; Mulligan SP; Christopherson RI Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):314-320. PubMed ID: 34886743 [TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860 [TBL] [Abstract][Full Text] [Related]
5. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822 [TBL] [Abstract][Full Text] [Related]
7. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484 [TBL] [Abstract][Full Text] [Related]
8. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Murray-Zmijewski F; Lane DP; Bourdon JC Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Bahnassy AA; Zekri AR; Salem SE; Abou-Bakr AA; Sakr MA; Abdel-Samiaa AG; Al-Bradei M Histol Histopathol; 2014 Feb; 29(2):207-16. PubMed ID: 23996743 [TBL] [Abstract][Full Text] [Related]
10. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924 [TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137 [TBL] [Abstract][Full Text] [Related]
12. p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Lefkimmiatis K; Caratozzolo MF; Merlo P; D'Erchia AM; Navarro B; Levrero M; Sbisa' E; Tullo A Cancer Res; 2009 Nov; 69(22):8563-71. PubMed ID: 19861536 [TBL] [Abstract][Full Text] [Related]
13. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442 [TBL] [Abstract][Full Text] [Related]
14. Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Marcel V; Petit I; Murray-Zmijewski F; Goullet de Rugy T; Fernandes K; Meuray V; Diot A; Lane DP; Aberdam D; Bourdon JC Cell Death Differ; 2012 May; 19(5):816-26. PubMed ID: 22075982 [TBL] [Abstract][Full Text] [Related]
15. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487 [TBL] [Abstract][Full Text] [Related]
16. The p53 family: same response, different signals? Chen X Mol Med Today; 1999 Sep; 5(9):387-92. PubMed ID: 10462750 [TBL] [Abstract][Full Text] [Related]
17. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513 [TBL] [Abstract][Full Text] [Related]
18. From p63 to p53 across p73. Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031 [TBL] [Abstract][Full Text] [Related]
19. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. Boominathan L PLoS One; 2010 May; 5(5):e10615. PubMed ID: 20485546 [TBL] [Abstract][Full Text] [Related]
20. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. Kommagani R; Payal V; Kadakia MP J Biol Chem; 2007 Oct; 282(41):29847-54. PubMed ID: 17716971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]